Ariad Pharmaceuticals Inc fka ARIA

[AmpleKind]

There is ZERO chance of front line.

AND

And without first line, Ariad is doomed to remain a standalone biotech.

Dognatic and totally unfounded assertions!
As the only drug that eliminates mutations, and gives patients
some hope of getting off drugs altogether, there's going to be
a lot of work (In the clinic and labs) to make it safe and maximally
beneficial to CML patients.

If I had CML, I would go for Iclusig first, especially if my doctor
was Dr.Cortez. Note that that sort of clinical excellence will at some
point become standard protocol, and continued experience in the
clinic will make Pona a much safer and desirable first line option.

bio.rese emphasizes all the risks, but ignores the benefits,
and the high probability of improved clinical outcomes as
oncologists gain experience with the drug.

That may resonate on boards, but not in medical situations
where patient benefit is paramount.